April 30, 2024Open Access

Supplementary Figure 5 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Key points are not available for this paper at this time.

Supplemental Figure 5 - Somatic Mutation Profiles in Baseline ctDNA

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Garmezy et al. (Tue,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper